DexCom, Inc. (DXCM)

Market Cap	25.45B
Revenue (ttm)	3.93B
Net Income (ttm)	666.90M
Shares Out	397.68M
EPS (ttm)	1.61
PE Ratio	39.75
Forward PE	32.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,667,927
Open	66.00
Previous Close	107.85
Day's Range	62.34 - 67.44
52-Week Range	62.34 - 142.00
Beta	1.16
Analysts	Buy
Price Target	114.06 (+78.22%)
Earnings Date	Jul 25, 2024

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into t...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 9,600
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM

Financial Performance

In 2023, DexCom's revenue was $3.62 billion, an increase of 24.49% compared to the previous year's $2.91 billion. Earnings were $541.50 million, an increase of 58.70%.

Analyst Forecast

According to 18 analysts, the average rating for DXCM stock is "Buy." The 12-month stock price forecast is $114.06, which is an increase of 78.22% from the latest price.

Price Target

$114.06

(78.22% upside)

Analyst Consensus: Buy